Ruxolitinib
Ruxolitinib, a JAK1 and JAK2 inhibitor used as a senomorphic
Written by Aaron CuhaReviewed Sep 2026
Also known as: Jakafi, Jakavi, Opzelura (topical), INCB018424
An approved JAK1 and JAK2 inhibitor that suppressed the senescence-associated secretory phenotype and improved physical function in aged mice. Its entire human evidence base is in myelofibrosis, where it shrinks spleens; the topical form carries a boxed warning for serious infections, mortality, malignancy, cardiovascular events and thrombosis.
Overview
Ruxolitinib is the clearest example of a senomorphic rather than a senolytic. A senolytic kills senescent cells. A senomorphic leaves them alive and shuts up their secretions.
The ageing case comes from a 2015 PNAS paper out of the Mayo Clinic Kogod Center. Senescent human preadipocytes and umbilical vein endothelial cells developed the senescence-associated secretory phenotype, and that SASP could be suppressed by targeting the JAK pathway, either by RNA interference or with JAK inhibitors. Conditioned medium from senescent human preadipocytes drew macrophages in and inflamed healthy fat tissue; medium from cells that had been treated with a JAK inhibitor was much less inflammatory. Giving a JAK inhibitor to aged mice for 10 weeks reduced both fat-tissue and systemic inflammation and improved physical function. The authors' own language is careful: their findings are consistent with a possible contribution of senescent cells and the SASP to age-related inflammation and frailty, and they speculate that SASP inhibition may contribute to alleviating frailty.
That is where the ageing evidence stops. No human trial of ruxolitinib for ageing, frailty or healthspan is registered.
What does exist is a substantial human record in a blood cancer. In COMFORT-I, 309 patients with intermediate-2 or high-risk myelofibrosis were randomised to ruxolitinib or placebo. The primary endpoint, a spleen volume reduction of 35 percent or more at 24 weeks, was reached by 41.9 percent on ruxolitinib against 0.7 percent on placebo. Symptom scores improved by half or more in 45.9 percent against 5.3 percent. Thirteen deaths occurred on ruxolitinib against 24 on placebo. Anaemia and thrombocytopenia were the commonest adverse events, and both patients who transformed to acute myeloid leukaemia were in the ruxolitinib arm.
That is a real drug doing real work in a serious disease, in people who are ill. It is not evidence about a healthy older adult, and the safety profile is the part that travels.
Mechanism of action
Ruxolitinib inhibits Janus kinase 1 and Janus kinase 2, the intracellular kinases that transduce signals from a large family of cytokine receptors through the STAT transcription factors. Much of the senescence-associated secretory phenotype is produced and reinforced through that pathway, so blocking JAK1 and JAK2 quietens the secretions without killing the senescent cell. Two consequences follow directly from the mechanism. The senescent cells remain, so the effect is suppressive and reverses when the drug stops, unlike a senolytic where the cell is gone. And JAK/STAT signalling is how the immune system communicates, so suppressing it suppresses host defence, which is why the class warnings read the way they do.
Human evidence
Extensive human evidence exists, and none of it is about ageing. Ruxolitinib has been through randomised phase 3 trials in myelofibrosis, polycythaemia vera and graft-versus-host disease, and is approved on the strength of them. No human trial has tested it for frailty, healthspan, inflammageing or any senescence endpoint.
- COMFORT-I, 309 randomised: 41.9 percent achieved a 35 percent or greater spleen volume reduction at 24 weeks against 0.7 percent on placebo.
- COMFORT-I symptom burden: 45.9 percent improved their total symptom score by half or more, against 5.3 percent on placebo.
- COMFORT-I mortality: 13 deaths on ruxolitinib against 24 on placebo, hazard ratio 0.50 (95 percent CI 0.25 to 0.98). In patients with an aggressive blood cancer, not in healthy older adults.
- Anaemia and thrombocytopenia were the most common adverse events on drug; both cases of transformation to acute myeloid leukaemia in the trial occurred in the ruxolitinib arm.
- The topical formulation, Opzelura, carries a United States boxed warning for serious infections, higher all-cause mortality, lymphoma and other malignancies, major adverse cardiovascular events and thrombosis, reflecting the JAK inhibitor class data in inflammatory disease.
- The oral formulation, Jakafi, does not carry a boxed warning, but its label warns for cytopenias, serious infection, non-melanoma skin cancer, lipid elevations, major adverse cardiovascular events, thrombosis and secondary malignancies particularly in current or past smokers.
- No registered human trial of ruxolitinib for ageing, frailty or healthspan was located.
What this does not tell you: None of this tells you what ruxolitinib does to a healthy older person. The trial populations had a life-limiting blood cancer, which changes the acceptable risk completely: an immunosuppressant that raises infection, cardiovascular and malignancy risk is a reasonable trade against myelofibrosis and an unreasonable one against the ordinary inflammation of ageing. The mouse data concern function over 10 weeks of dosing, not lifespan, and because a senomorphic suppresses rather than removes, any benefit would require indefinite dosing with the safety profile running the whole time.
Reading the research record
The gap between what ruxolitinib has been shown to do and what it is being discussed as doing is unusually wide, and the boxed warning belongs on the same page as the senomorphic claim rather than in a footnote.
The class safety signal is real and it came from a randomised trial. The JAK inhibitor boxed warning covering serious infections, higher all-cause mortality, malignancy, major adverse cardiovascular events and thrombosis was applied across the class after safety findings in inflammatory disease, and it appears on the topical ruxolitinib label. The oral product, approved earlier and for cancer, does not carry a boxed warning, but does carry labelled warnings for cytopenias, serious infection, skin cancer, cardiovascular events, thrombosis and secondary malignancies. A person considering a JAK inhibitor for inflammation of ageing is much closer to the inflammatory-disease population that generated the warning than to the myelofibrosis population that generated the efficacy data.
The senomorphic and senolytic distinction also changes the risk arithmetic. A senolytic is given in short pulses because the cells it kills take time to come back, so exposure is intermittent. A senomorphic only works while it is present, which means continuous exposure to an immunosuppressant, indefinitely, for a benefit measured so far in aged mice.
The evidence, charted
Fig. 1 · evidence composition
2of 4 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Evidence spans 4 distinct years, 2012 to 2017, counted from the citation list on this page. The newest citation on file is from 2017, more than five years ago; the published record may have gone quiet.
Fig. 3 · legal status at a glance
US
Approved
UK
Approved
AU
Approved
CA
Approved
Approved in all four jurisdictions shown. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Animal2015
JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age
Human cells in culture plus aged mice. Senescent human preadipocytes and HUVECs developed a SASP that was suppressed by JAK-pathway RNAi or JAK inhibitors, and conditioned medium from JAK-inhibitor-treated senescent cells was much less proinflammatory. Giving a JAK inhibitor to aged mice for 10 weeks alleviated adipose and systemic inflammation and enhanced physical function. The authors state their findings are consistent with a possible contribution of senescent cells to age-related frailty and speculate about SASP inhibition; they do not report a human outcome.
Proceedings of the National Academy of Sciences - Human2012
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
COMFORT-I, NCT00952289, 309 patients with intermediate-2 or high-risk myelofibrosis. Spleen volume reduction of at least 35 percent at 24 weeks: 41.9 percent on ruxolitinib against 0.7 percent on placebo. Total symptom score improved by at least 50 percent in 45.9 percent against 5.3 percent. Thirteen deaths on ruxolitinib against 24 on placebo (hazard ratio 0.50, 95 percent CI 0.25 to 0.98). Anaemia and thrombocytopenia were the commonest adverse events; both transformations to acute myeloid leukaemia were in the ruxolitinib arm. This is a cancer trial, not an ageing trial.
New England Journal of Medicine - Human2017
Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial
The five-year follow-up of the same myelofibrosis trial, reporting durability of spleen response and long-term safety in that population. Still a cancer population, still no ageing endpoint.
Journal of Hematology and Oncology - Review2016
Perspective: Targeting the JAK/STAT pathway to fight age-related dysfunction
A review setting out the case for JAK/STAT inhibition as a geroscience strategy and its unknowns. A perspective article, not new data.
Pharmacological Research
Frequently asked questions
Does ruxolitinib slow ageing?
Unknown in people. In aged mice, 10 weeks of a JAK inhibitor reduced inflammation and improved physical function. No human trial has tested it for ageing, frailty or healthspan.
Is it a senolytic?
No. It is a senomorphic. It does not kill senescent cells, it suppresses their inflammatory secretions, so the effect lasts only as long as you keep taking it.
What are the risks?
Serious ones. Topical ruxolitinib carries a United States boxed warning for serious infections, higher all-cause mortality, lymphoma and other malignancies, major adverse cardiovascular events and thrombosis. The oral form has no boxed warning but is labelled for cytopenias, serious infection, non-melanoma skin cancer, lipid elevations, cardiovascular events, thrombosis and secondary malignancies. Anaemia and low platelets are the commonest problems on drug.
What is it actually approved for?
Myelofibrosis, polycythaemia vera and steroid-refractory graft-versus-host disease as the oral tablet, and atopic dermatitis and non-segmental vitiligo as a cream. Nothing to do with ageing.
Could I take a low dose for inflammation?
There is no trial telling you what dose to use, for how long, or what it would achieve. It is a prescription immunosuppressant, and the population that generated the class safety warning was people taking JAK inhibitors for inflammatory conditions, which is the closest analogue to that use.